Shares of Biogen (BIIB) were lower Tuesday after the company resolved a dispute with Forward Pharma (FWP) over its multiple sclerosis drug. Biogen agreed to pay Forward $1.25 billion, which will give it a license to all intellectual property owned by Forward. Under the agreement, Biogen will also have to pay the Denmark-based company royalties of 10% to 20% of net sales of Biogen products approved for the treatment of multiple sclerosis.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.